-
Product Insights
NewNet Present Value Model: Freeline Therapeutics Holdings Plc’s FLT-201
Empower your strategies with our Net Present Value Model: Freeline Therapeutics Holdings Plc's FLT-201 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewMyocardial Infarction – Drugs In Development, 2024
Empower your strategies with our Myocardial Infarction – Drugs In Development, 2024 report and make more profitable business decisions. Myocardial infarction is the irreversible necrosis of heart muscle secondary to prolonged ischemia. Symptoms include pain, fullness, and/or squeezing sensation of the chest; jaw pain, toothache, or headache; shortness of breath; nausea, vomiting, and/or general epigastric discomfort; sweating, heartburn and/or indigestion; arm pain; upper back pain; and general malaise (vague feeling of illness). The Myocardial Infarction drugs in development market research report...
-
Product Insights
NewPost-Myocardial Infarction – Drugs In Development, 2024
Empower your strategies with our Post-Myocardial Infarction – Drugs In Development, 2024 report and make more profitable business decisions. After myocardial infarction (MI), patients are at a greater risk of heart failure. This happens when blood flow to the heart muscle is blocked. Long-term beta-blocker use after MI is associated with a reduced risk of reinfarction and death. Thus, it is critical to frequently re-evaluate beta-blocker eligibility among patients after MI with HF. The Post-Myocardial Infarction drugs in development market research...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FLT-201 in Gaucher Disease Type I
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FLT-201 in Gaucher Disease Type I report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FLT-201 in Gaucher Disease Type I Drug Details: FLT-201...
-
Company Profile
Freeline Therapeutics Holdings Plc – Company Profile
Freeline Therapeutics Holdings Plc (Freeline), a subsidiary of Syncona Ltd, is a biotechnology company that develops transformative gene therapies for the treatment of debilitating diseases. The company utilizes the AAV vector and AAVS3 platform to deliver functional copies of therapeutic genes into human liver cells. Its platform consists of in-house capabilities in research and clinical development. Freeline’s product pipeline includes FLT190, a liver-directed gene therapy to treat fabry disease and FLT201 for the treatment of gaucher disease. The company works...
Add to Basket -
Product Insights
Gaucher Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Gaucher disease is a rare genetic disorder occurs due to lacks an enzyme called glucocerebrosidase. Symptoms include cognitive impairment, enlarged spleen, severe swelling, lung disease, fatigue, and seizures. Treatment includes enzyme replacement therapy. The Gaucher Disease pipeline market research report provides comprehensive information on the therapeutics under development for Gaucher Disease (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological...